Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
IPO Year: 2018
Exchange: NYSE
Website: arcusbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2024 | $20.00 | Neutral | H.C. Wainwright |
| 10/8/2024 | $29.00 | Overweight | Wells Fargo |
| 11/18/2022 | $33.00 | Neutral | BofA Securities |
| 10/11/2022 | $40.00 | Overweight | Morgan Stanley |
| 11/19/2021 | $42.00 → $53.00 | Buy | Citigroup |
| 11/19/2021 | $48.00 → $60.00 | Overweight | Barclays |
| 11/18/2021 | $68.00 → $100.00 | Outperform | SVB Leerink |
| 11/9/2021 | $45.00 → $48.00 | Overweight | Barclays |
| 10/15/2021 | $57.00 | Buy | BTIG Research |
| 8/6/2021 | $63.00 → $68.00 | Outperform | SVB Leerink |
10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December: Evercore 7th Annual HealthCONx Conference Date: Tuesday, December 3rd, 2024 Location: Coral Gables, FL Format: Fireside chat & 1x1 meetings Time: 7:55 a.m. ET Citi 2024 Global Healthcare Conference Date: Wednesday, December 4th, 2024 Location: Miami, FL Format: 1x1 meetings only Live webcasts of the fireside chats and panel will be available by visiting the "Investors & Media" section of the Arcus
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company's common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and restricted stock units to acquire a total of 7,050 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January
Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a potential best-in-class profile Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig, an investigational PD-1/CTLA-4 bispecific antibody, in patients with immuno-oncology (IO)-naive ccRCC Data from the randomized ARC-
Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy A 36% reduction in risk of death (HR=0.64) was observed for domvanalimab plus zimberelimab compared to zimberelimab alone; zimberelimab reached a median overall survival of two years while the median overall survival for domvanalimab plus zimberelimab was not reached Treatment-related adverse events leading to treatment discontinuation were low (10.5%) for the combination of domvanalimab and zimberelimab relative to chemotherapy (23.5%) Arcus will discuss these results on its earnings call at 2:00 PM
Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC), will be presented in a late-breaking poster presentation An oral presentation will highlight data from an Investigator Sponsored Trial for domvanalimab and zimberelimab in anti-PD-1 refractory hepatocellular carcinoma, demonstrating further proof of concept for the Fc-silent anti-TIGIT antibody domvanalimab Arcus will discuss the ARC-10 results in more detail on its earnings call at 2:00 PM PT / 5:00 PM ET on Wednesday, November 6, 2024 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-s
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 28,600 shares of the Company's common stock at an exercise price per share of $17.33, which was the closing price on October 23, 2024, and restricted stock units to acquire a total of 14,300 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January
Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20, a Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma (ccRCC) Low rate of primary progression (19%) and high rate of disease control (81%) was observed in the 100mg expansion cohort with many of those patients still on treatment Arcus will host a conference call to discuss these results, including results from the 50mg expansion cohort, at 5:00 AM PT / 8:00 AM ET today Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinati
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended September 30th, 2024. Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 940081. Participants may also register for the call online using the following link: https://www.netroadshow.com/
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 24,100 shares of the Company's common stock at an exercise price per share of $17.47, which was the closing price on October 8, 2024, and restricted stock units to acquire a total of 12,050 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January
Data from the 100mg expansion cohort of ARC-20, a Phase 1/1b study of casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in an oral plenary session by Dr. Toni Choueiri, Dana-Farber Cancer Institute. Two posters will be presented on the preclinical evaluation and human pharmacokinetics/ pharmacodynamics of casdatifan, respectively, and a third poster will be presented on AB801, Arcus's AXL inhibitor. Arcus will also host a conference call to discuss the ARC-20 results at 5:00 AM PT / 8:00 AM ET on Thursday, October 24, 2024. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules an
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo
Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Dimitry S.A. Nuyten, M.D., Ph.D has been appointed chief medical officer (CMO) effective August 1, 2022. In his role as CMO, Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the a
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 31,600 shares of the Company’s common stock at an exercise price per share of $30.83, which was the closing price on January 8, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08. About Arcu
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. have joined the Company’s Board of Directors. Dr. Perlman will also serve as a member of Arcus’s Nominating and Corporate Governance Committee. Drs. Perlman and Quigley both have outstanding track records of success working in innovative and intensely competitive drug discovery and development organizations, including in the fields of oncology and immuno-oncology. “As we head into a pivotal year for Arcus that will include multiple randomize
Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a potential best-in-class profile Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig, an investigational PD-1/CTLA-4 bispecific antibody, in patients with immuno-oncology (IO)-naive ccRCC Data from the randomized ARC-
Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy A 36% reduction in risk of death (HR=0.64) was observed for domvanalimab plus zimberelimab compared to zimberelimab alone; zimberelimab reached a median overall survival of two years while the median overall survival for domvanalimab plus zimberelimab was not reached Treatment-related adverse events leading to treatment discontinuation were low (10.5%) for the combination of domvanalimab and zimberelimab relative to chemotherapy (23.5%) Arcus will discuss these results on its earnings call at 2:00 PM
Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20, a Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma (ccRCC) Low rate of primary progression (19%) and high rate of disease control (81%) was observed in the 100mg expansion cohort with many of those patients still on treatment Arcus will host a conference call to discuss these results, including results from the 50mg expansion cohort, at 5:00 AM PT / 8:00 AM ET today Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinati
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended September 30th, 2024. Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 940081. Participants may also register for the call online using the following link: https://www.netroadshow.com/
Data from the 100mg expansion cohort of ARC-20, a Phase 1/1b study of casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in an oral plenary session by Dr. Toni Choueiri, Dana-Farber Cancer Institute. Two posters will be presented on the preclinical evaluation and human pharmacokinetics/ pharmacodynamics of casdatifan, respectively, and a third poster will be presented on AB801, Arcus's AXL inhibitor. Arcus will also host a conference call to discuss the ARC-20 results at 5:00 AM PT / 8:00 AM ET on Thursday, October 24, 2024. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules an
Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1/1b study in clear cell renal cell carcinoma (ccRCC), are expected to be presented at a medical conference in the fourth quarter of 2024 PEAK-1, the initial Phase 3 study evaluating casdatifan in combination with cabozantinib, is expected to begin in the first half of 2025 Patient enrollment has completed for the Phase 3 study STAR-221 (upper gastrointestinal (GI) cancers) for domvanalimab plus zimberelimab and chemotherapy Arcus is well-positioned to advance its full pipeline with $1.0 billion in cash, cash equivalents and marketable securities and runway into 2027 Conference call today at 2:00 PM PT / 5:00 P
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended June 30th, 2024. Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 287576. To access the live webcast and accompanying slide presentation, please visit the "Investors & Media" section of the Arcu
Arcus data will be disclosed in two oral presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Updated data, including median progression-free survival (PFS), from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper GI cancers Data, including overall survival (OS) and PFS, from ARC-9 evaluating an etrumadenant plus zimberelimab-based treatment combination in third-line metastatic colorectal cancer Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1/1b study of casdatifan in clear cell renal cell carcinoma (ccRCC), are expected to be presented in the second half of 2024 Completion of enrollment fo
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, May 8th, 2024 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2024. Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 034427. To access the live webcast and accompanying slide presentation, please visit the "Investors & Media" section of the
Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical needs and largest market opportunities Pharmacokinetic (PK), pharmacodynamic (PD), safety and early efficacy data, including initial observations from the expansion cohort, from ARC-20, support potential for casdatifan (AB521) to result in greater HIF-2a inhibition than the marketed competitor; expansion cohort data expected to be presented in the second half of 2024 Multiple datasets expected to be presented in the first half of 2024 including EDGE-Gastric for domvanalimab + zimberelimab +
This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. This is the fourth option exercise by Taiho to an Arcus program. In exchange for the exclusive license of quemliclustat, Taiho will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercialization milestones, and, if any products from the program are approved, will pay royalties on net sales of such products.
Arcus Biosciences (NYSE:RCUS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Arcus Biosciences, presenting an average target of $34.25, a high estimate of $44.00, and a low estimate of $25.00. Observing a downward
Barclays analyst Peter Lawson maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and lowers the price target from $35 to $25.
Cantor Fitzgerald analyst Alethia Young reiterates Arcus Biosciences (NYSE:RCUS) with a Overweight.
Truist Securities analyst Asthika Goonewardene maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $50 to $44.
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient populationArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the completion of patient enrollment for STAR-221, a Phase 3 study in collaboration with Gilead Sciences, evaluating the combination of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastr
On Saturday, Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences Inc (NYSE:RCUS) released longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. The updated data show consistent objective response rate (ORR) and provide mature progression-free survival (PFS) in patients with a locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma (upper GI cancers). Related: Gilead’s Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer. The ongoing, multi-arm, global Phase 2 EDGE-Gastric study is evaluating the safety and efficacy of various combinations of the Fc-silen
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $36 to $38.
Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody zimberelimab, FOLFOX chemotherapy and bevacizumab (EZFB) in third-line metastatic colorectal cancer (mCRC). These results will be presented today during an oral session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Zev A. Wainberg, M.D., MSc, Co-Director of the GI Oncology Program at University of California Los Angeles and a principal investigator of the ARC-9 trial (Abstract 3508). In Cohor
Gainers Cue Health (NASDAQ:HLTH) shares moved upwards by 42.1% to $0.13 during Friday's pre-market session. The company's market cap stands at $21.3 million. Innovative Eyewear (NASDAQ:LUCY) stock rose 24.73% to $0.23. The market value of their outstanding shares is at $4.0 million. SCWorx (NASDAQ:WORX) shares increased by 17.02% to $2.2. The company's market cap stands at $2.6 million. Arcus Biosciences (NYSE:RCUS) stock rose 16.33% to $18.94. The company's market cap stands at $1.7 billion. Biora Therapeutics (NASDAQ:BIOR) stock moved upwards by 15.01% to $0.57. The market value of their outstanding shares is at $20.5 million. Jin Medical International (NASDAQ:ZJYL) shares moved upwa
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00
Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00
BofA Securities initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $33.00
Morgan Stanley initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $40.00
Citigroup reiterated coverage of Arcus Biosciences with a rating of Buy and set a new price target of $53.00 from $42.00 previously
Barclays reiterated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $60.00 from $48.00 previously
SVB Leerink reiterated coverage of Arcus Biosciences with a rating of Outperform and set a new price target of $100.00 from $68.00 previously
Barclays reiterated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $48.00 from $45.00 previously
BTIG Research resumed coverage of Arcus Biosciences with a rating of Buy and set a new price target of $57.00
SVB Leerink reiterated coverage of Arcus Biosciences with a rating of Outperform and set a new price target of $68.00 from $63.00 previously
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)